Greater early postprandial suppression of endogenous glucose production is achieved with fast-acting insulin aspart compared to insulin aspart

被引：0
|
作者：
Pieber, T. R. [1 ]
Basu, A. [2 ]
Hansen, A. K. [3 ]
Sach-Friedl, S. [1 ]
Thomsen, K. M. D. [3 ]
Basu, R. [2 ]
Haahr, H. [3 ]
机构：
[1] Med Univ Graz, Graz, Austria
[2] Mayo Clin, Rochester, MN USA
[3] Novo Nordisk, Soborg, Denmark
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
690
引用
收藏
页码：S315 / S315
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial
    Bode, Bruce W.
    Iotova, Violeta
    Kovarenko, Margarita
    Laffel, Lori M.
    Rao, Paturi V.
    Deenadayalan, Srikanth
    Ekelund, Magnus
    Larsen, Steffen Falgreen
    Danne, Thomas
    DIABETES CARE, 2019, 42 (07) : 1255 - 1262
  • [22] Fast-Acting Insulin aspart (faster aspart) - Clinical Data on Application in Type 1 and 2 Diabetes
    Jaeckel, E.
    DIABETES STOFFWECHSEL UND HERZ, 2018, 27 (06): : 313 - 319
  • [23] Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide
    Kildegaard, Jonas
    Buckley, Stephen T.
    Nielsen, Rasmus H.
    Povlsen, Gro K.
    Seested, Torben
    Ribel, Ulla
    Olsen, Helle B.
    Ludvigsen, Svend
    Jeppesen, Claus B.
    Refsgaard, Hanne H. F.
    Bendtsen, Kristian M.
    Kristensen, Niels R.
    Hostrup, Susanne
    Sturis, Jeppe
    PHARMACEUTICAL RESEARCH, 2019, 36 (03)
  • [24] Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
    Hanne Haahr
    Thomas R. Pieber
    Chantal Mathieu
    Theis Gondolf
    Masanari Shiramoto
    Lars Erichsen
    Tim Heise
    Clinical Pharmacokinetics, 2019, 58 : 639 - 649
  • [25] Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide
    Jonas Kildegaard
    Stephen T. Buckley
    Rasmus H. Nielsen
    Gro K. Povlsen
    Torben Seested
    Ulla Ribel
    Helle B. Olsen
    Svend Ludvigsen
    Claus B. Jeppesen
    Hanne H. F. Refsgaard
    Kristian M. Bendtsen
    Niels R. Kristensen
    Susanne Hostrup
    Jeppe Sturis
    Pharmaceutical Research, 2019, 36
  • [26] Efficacy and safety of fast-acting insulin aspart versus insulin aspart in children and adolescents with type 1 diabetes from Japan
    Kawamura, Tomoyuki
    Kikuchi, Toru
    Horio, Hiroshi
    Rathor, Naveen
    Ekelund, Magnus
    ENDOCRINE JOURNAL, 2021, 68 (04) : 409 - 420
  • [27] Hypoglycaemia with mealtime fast-acting insulin aspart versus insulin aspart across two large type 1 diabetes trials
    De Block, C.
    Carlson, A.
    Rose, L.
    Gondolf, T.
    Gorst-Rasmussen, A.
    Boesgaard, T. W.
    Lane, W.
    DIABETOLOGIA, 2018, 61 : S31 - S32
  • [28] GREATER EARLY INSULIN EXPOSURE AND GLUCOSE-LOWERING WITH FASTER-ACTING INSULIN ASPART VS INSULIN ASPART IN JAPANESE SUBJECTS WITH TYPE 1 DIABETES
    Shiramoto, M.
    Nishida, T.
    Hansen, A. K.
    Haahr, H.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A118 - A119
  • [29] Hypoglycemia with Mealtime Fast-Acting Insulin Aspart vs. Insulin Aspart Across Two Large Type 1 Diabetes Trials
    De Block, Christophe
    Carlson, Anders
    Rose, Ludger
    Gondolf, Theis
    Gorst-Rasmussen, Anders
    Lane, Wendy
    DIABETES, 2018, 67
  • [30] Improved glycaemic control with carbohydrate counting for adjustment of fast-acting insulin aspart versus insulin aspart in subjects with type 1 diabetes
    Twigg, Stephen
    Philis-Tsimikas, Athena
    Bode, Bruce
    Franek, Edward
    Rose, Ludger
    Buchholtz, Kristine
    Demissie, Marek
    Pieber, Thomas R.
    CLINICAL ENDOCRINOLOGY, 2018, 89 : 64 - 64
12345